



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/510,560	02/22/2000	Kenneth Iain Cumming	00.1090.US	3011
<div>7590 08/23/2007 SYNNESTVEDT & LECHNER LLP ATTN: PATRICK J. KELLY, ESQ. SUITE 2600 ARAMARK TOWER 1101 MARKET STREET PHILADELPHIA, PA 19107-2950</div>				
			EXAMINER LUNDGREN, JEFFREY S	
			ART UNIT 1639	PAPER NUMBER
			MAIL DATE 08/23/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 09/510,560	Applicant(s) CUMMING ET AL.	
	Examiner Jeff Lundgren	Art Unit 1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 May 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 178-257 is/are pending in the application.
- 4a) Of the above claim(s) See Continuation Sheet is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 178-184, 186, 188, 193, 194, 197-206, 209, 211-224, 226, 228, 233, 234, 237, 238, 240, 241, 244-247, 250, 251 and 253-256 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Continuation of Disposition of Claims: Claims withdrawn from consideration are 185,187,189-192,195,196,207,208,210,225,227,229-232,235,236,239,242,243,248,249,252 and 257.

DETAILED ACTION***Election and Status of the Claims***

Applicant's election of Group I in the reply filed on May 11, 2007, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 178-257 are pending; claims 185, 187, 189-192, 195, 196, 207, 208, 210, 225, 227, 229-232, 235, 236, 239, 242, 243, 248, 249, 252 and 257 are withdrawn as being directed to a non-elected invention (i.e., non-elected species from Action mailed on March 18, 2005, and May 3, 2007); claims 178-184, 186, 188, 193, 194, 197-206, 209, 211-224, 226, 228, 233, 234, 237, 238, 240, 241, 244-247, 250, 251 and 253-256, are the subject of the Office Action below.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 178-184, 186, 188, 193, 194, 197-206, 209, 211-224, 226, 228, 233, 234, 237, 238, 240, 241, 244-247, 250, 251 and 253-256, are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Independent claims 178, 211, 240 and 246, and all dependent claims, are indefinite for because Applicants' use of the transition language "consisting essentially of" is improper. Use of the claim language "consisting essentially of" usually excludes components that have a "material effect" different from the recited limitations, but is open to components that do not have a "material effect" on recited limitations. *See Kim v. ConAgra Foods Inc.*, Fed. Cir. docket 05-1414-1420, published September 20, 2006; *see also PPG Industries Inc. v. Guardian Industries Corp.*, 2d U.S.P.Q. 1352 (Fed. Cir. 1998). Specifically, it is not clear from the language of the claim itself, Applicants' own specification, or any of art of record, what material effects Applicants intend to capture. In the instant case, Applicants have not provided any guidance as to what elements would constitute a "material effect" as it pertains to the

Art Unit: 1639

pharmaceutical composition, such as the active, the enhancer, or any other component for that matter. For example, it is not clear if sustained release component will have a material effect on the composition since enhancers increase absorption, yet sustained release coatings affect the release rate, and in turn then affect absorption. See also claim 239 where Applicants claim an "enhancer combination", yet independent claim 211 claims only a single enhancer.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

The rejection of new claims 178-181, 183 and 240, are rejected under 35 U.S.C. § 102(b) as being anticipated by Bachynsky *et al.*, Irish Patent No. (11) 63119, published on March 22, 1995, and Bachynsky *et al.*, U.S. Patent No. 5,190,748, issued on March 2, 1993, is maintained in modified form due to Applicants canceling all claims and presenting all new claims.

Claim 178, 211, 240 and 246, are directed to a composition comprising a blend of a hydrophilic drug or macromolecular drug, a an enhancer, wherein the enhancer is a salt of a medium chain fatty acid, and the enhancer and composition are solids at room temperature.

Bachynsky teaches a blend of a "macromolecular"/"hydrophilic" drug (*i.e.*, ceftriaxone), and a salt of a medium chain fatty acid having a carbon chain length of from 6 to 20 carbon atoms (*i.e.*, sodium caprylate), with optional constituents Laureth-12 and Witepsol™ H15 (the '748 patent, col. 12, lines 59-65). The blend, as well as each of the drug, medium chain fatty acid salt, and the other constituents, each are solids at room temperature. The blend is capable of forming an oral dosage form (such as claims 120, 143 and 153), and the sodium caprylate would

Art Unit: 1639

serve as an enhancer. Bachynsky also quite clearly teaches another formulation comprising sodium caprylate as an enhancer with ceftriaxone:

“Absorption was also evaluated using a formulation composed of 300 mg of ceftriaxone sodium salt, 200 mg of sodium caprylate, 75 mg of Laureth-12 and 415 mg of Witapsol H15.”

Bachynsky, col. 13, lines 14-21. Bachynsky also teaches a compressed tablet or pill:

“The preferred method of orally administering the combination of antibacterial compound and absorption enhancing system in accordance with this invention is in the form of an enteric coated entity, and more specifically, an enteric coated solid dosage form. The formulation can be filled into a hard- or soft-shell capsule or, if the formulation is a liquid, absorbed onto a suitable carrier to make a free flowing powder and then filled into the capsule or, alternatively, *compressed* into a pill or *tablet*. Still other possible dosage forms include microcapsule or beadlet forms of the antibacterial compound mixed with the absorption enhancing system which may thereafter be encapsulated in an enteric coated capsule.”

Bachynsky, col. 8, lines 13-27 (emphasis added). The claims ratio of the drug to enhancer taught by Bachynsky is 0.3:1 to 1.5:1 (see table, page 14, lines 15-19), and a therapeutically effective amount of the active is used for treatment (col. 1, lines 10-21).

This formulation is formed in a hard shell gelatin capsule, and also teaches tablets and pills (see Abstract) and therefore meets the limitations of claims 180, 200 and 203.

Further, the capsule has an enteric coating (col. 8, lines 18-26), such as polyvinyl acetate phthalate (col. 12, lines 65-66), or methacrylic acid and its ester (col. 8, lines 45-46), which are “rate controlling” and “delays release”, and the enteric coated tablet is effectively multilayered, and therefore meets the limitations of claims 179, 181, 215-221. Since Bachynsky teaches an enteric coated tablet, the tablet is effectively multilayered (claims 124, 129, 138, 139, 157, 171 and 172).

Bachynsky teaches tablets and beadlets (*i.e.*, meets the limitations of either particles or pellets), and therefore meets the limitations of claims 123, 130, 131, 136, 154, 156, 162, 163, 164, 169.

As in claims 126 and 159, Bachynsky discloses HPMC, which is “rate controlling” (col. 8, lines 60-66).

The rejection of new claims 178-184, 186, 188, 193, 194, 197-204, 209, 211-224, 226, 228, 233, 234, 237-241, 244-247, 250, 251 and 253-256, under 35 U.S.C. § 102(b) as being anticipated by Watts *et al.*, International Patent Application Publication WO 97/05903, published on February 20, 1997, is maintained in modified form due to Applicants canceling all claims and presenting all new claims.

Watts discloses a drug delivery composition (tablet, capsule, including a gelatin capsule, and a pellet) for colonic delivery through oral administration (see Abstract; accordingly this is a delayed release formulation) comprising a drug (e.g. polypeptide and polysaccharide including heparin and low molecular weight heparin; see page 8), and an absorption promoter (see page 24), such as low molecular weight heparin (see Example 10 on page 22 of the PCT). This formulation is a solid at room temperature, as is the enhancer, and is provided as a capsule. It is also provided with the auxiliary excipient Labrasol, which instead of being an enhancer is considered a dispersing agent (see Detailed Description). Watts also teaches the use of a single enhancer with insulin and capric acid (see Figure 3, and description thereof) Watts teaches that the absorption promoter comprises a fatty acid or a salt thereof, where the fatty acid has between 6 and 16 carbon atoms, for example capric acid (Example 10) or its sodium salt (e.g. see pages 5, 24, claims 1 and 3) which can be used *alone* or in admixture with a fatty acid derivative (e.g. mono/diglycerides: see pages 5-7) to obtain synergy. For example, Watts states:

“It has been known for some time that sodium caprate can act as an absorption promoting agent, probably by the perturbation of membranes or modification of tight junctions between cells (Kajii et al. J. Pharm. Sci. 77 390, 1988).”

Watts, paragraph bridging pages 2 and 3.

Watts further teaches that the drug can be chosen from insulin, calcitonin, LHRH, buserelin, goserelin, vasopressin, heparin, and more (p 8, 11-12, and p 24, claim 6). Watts teaches that the composition is formulated in a capsule (e.g. hard/soft gelatin), tablet, pellet, or multiparticulate capsule or tablet which is comprised of or coated with a material which is dissolved by the conditions found in the intestines e.g. “rate-controlling” (e.g. sustained release), such as a cellulose ester, HPMC (e.g. see page 9, lines 14-29) or a methacrylic acid polymer

Art Unit: 1639

(pages 10-12) for in vivo therapeutic administration to a patient (see pages 14-15). In Example 10 (page 22), Watts teaches:

“Into a glass vial was weighed 875 mg of LABRASOL™ and 875 mg of capric acid. The vial contents were heated to 40 °C. until the capric acid has dispersed. 1741 mg of low molecular weight heparin (LMWH. 145 IU/mg) was added to the melted LABRASOL.TM./capric acid mixture. Into each of eight starch capsules was weighed 349 mg of the mixture, equivalent to 174 mg of LMWH, 87.5 mg LABRASOL.TM. and 87.5 mg capric acid. Each of four pigs weighing approximately 65 kg was administered two of the capsules into the ileal fistula as described in Example 1. As controls, each pig was administered two starch capsules containing 174 mg of LMWH powder. Plasma samples were collected and the anti-factor Xa activity measured using a proprietary assay kit. By measuring the anti-factor Xa activity in standards containing known quantities of LMWH. the LMWH content of the pig plasma samples was calculated. The plasma LMWH concentration vs. time profiles for the enhancer and control formulations are shown in FIG. 10. The formulation containing LABRASOL.TM. and capric acid was effective in enhancing colonic absorption of LMWH.”

Watts, page 22.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. § 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1639

The rejection of claims 178-184, 186, 188, 193, 194, 197-206, 209, 211-224, 226, 228, 233, 234, 237-241, 244-247, 250, 251 and 253-256, rejected under 35 U.S.C. § 103(a) as being unpatentable over Watts, in view of Mulqueen *et al.*, U.S. Patent No. 6,017,559, issued on January 25, 2000, is maintained in modified form due to Applicants canceling all claims and presenting all new claims.

The limitations of claim 178-184, 186, 188, 193, 194, 197-204, 209, 211-224, 226, 228, 233, 234, 237-241, 244-247, 250, 251 and 253-256, as well as the corresponding teachings of Watts, are set forth above and are hereby incorporate by reference.

Claims 205 and 206 are directed to two or more populations of particles, which is not explicitly stated by Watts.

Mulqueen teaches a method for preparing microcapsules with bimodal and multimodal distributions that are solids and may be used to be placed in finished capsules. Mulqueen states:

“It is very difficult by conventional methods to produce emulsions with particle sizes and particle size distributions which are both easily reproducible, and easily controlled. By contrast, many of the templating agents which can be employed in accordance with the present invention can easily be produced in particle size distributions which are easy to control, and in particular which have a narrow particle size distribution, or which have a multimodal (e.g., a bimodal) particle size distribution.”

Mulqueen, paragraph bridging cols. 1 and 2; and:

“The non-aqueous phase employed in the production of such microcapsules may contain chosen amounts of plasticizer for the wall of the finished capsule, thus enabling control of the release kinetics of the finished microcapsules.”

Mulqueen, col. 5, line 59-62.

One of ordinary skill in the art would have had a reasonable expectation of success in arriving at the invention as claimed because each of Watts and Mulqueen are directed to the pharmaceutical arts. While Watts is primarily focused on providing certain peptide based therapeutics in the presence of an enhancer, Watts certainly recognizes the variety of pharmaceutical formulation considerations and forms that may be applied depending on the therapy, including tablets and capsules, as well as various controlled/delayed release formulations. Mulqueen provides a solution for improved production control of certain

Art Unit: 1639

pharmaceutical forms, namely, controlled size microsphere production. Mulqueen states that his invention is useful in the production of multimodal size distributions of microspheres, which he suggests have the advantage of providing the a range of delivery rates for the pharmacologists intended delivery profile. Therefore, the invention as whole is *prima facie* obvious over the art of record.

Conclusions

No claim is allowable.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

If Applicants should amendment the claims, a complete and responsive reply will clearly identify where support can be found in the disclosure for each amendment. Applicants should point to the page and line numbers of the application corresponding to each amendment, and provide any statements that might help to identify support for the claimed invention (*e.g.*, if the amendment is not supported *in ipsis verbis*, clarification on the record may be helpful). Should Applicants present new claims, Applicants should clearly identify where support can be found in the disclosure.


Art Unit: 1639

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jeff Lundgren whose telephone number is 571-272-5541. The Examiner can normally be reached from 7:00 AM to 5:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, James Schultz, can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JSL


J. DOUGLAS SCHULTZ, PH.D.
SUPERVISORY PATENT EXAMINER